Status: Recruiting
Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients
A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.
Participants needed: 98
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Dec 17, 2024Locations: 2
Eligibility criteria
1. Pathologically confirmed pancreatic ductal epithelial malignant tumors; [+6]
1. Known allergy or intolerance to any component of investigational Oral Immunon... [+9]